Quantcast
Last updated on April 24, 2014 at 5:22 EDT

Latest Triamcinolone Stories

2013-10-02 08:30:45

- Oral presentation at ACR will highlight results from first head-to-head dose-ranging study comparing FX006 with approved injectable dose of commonly prescribed, immediate release steroid for patients with osteoarthritis (OA) of the knee - BURLINGTON, Mass., Oct. 2, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. announced today that new data from a Phase 2b dose-ranging trial of the company's lead compound, FX006, in osteoarthritis (OA) has been accepted for an oral presentation...

2013-08-12 08:30:32

ALLEGAN, Mich., Aug. 12, 2013 /PRNewswire/ -- Perrigo Company (NYSE: PRGO; TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug applications for fluocinolone acetonide scalp oil, 0.01%, the generic equivalent to Derma-Smoothe/FS® Scalp Oil, and fluocinolone acetonide topical oil, 0.01%, the generic equivalent to Derma-Smoothe/FS® Body Oil. Perrigo expects to begin shipments of both products next month....

2013-07-31 23:18:37

David P. Skoner, MD, of Allegheny General Hospital was chosen to represent the opinions of major national allergy medicine societies in opposing the over-the-counter sale of triamcinolone acetonide (Nasacort) to kids and adults. Silver Spring, Md. (PRWEB) July 31, 2013 David P. Skoner, MD, Director of the Division of Allergy, Asthma and Immunology, Department of Medicine at Allegheny General Hospital (AGH), will testify today before the U.S. Food and Drug Administration in opposition to...

2013-07-31 20:21:31

- Treats Seasonal and Year-round Nasal Allergy Symptoms in Adults and Children - PARIS, July 31, 2013 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration's (FDA) Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort(®) AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S. (Logo: http://photos.prnewswire.com/prnh/20110616/NY20158LOGO)...

2013-04-18 16:27:48

WOBURN, Mass., April 18, 2013 /PRNewswire/ -- Flexion Therapeutics, Inc. announced today the presentation of a poster titled "FX006 prolongs the residency of triamcinolone acetonide in the synovial tissues of patients with knee osteoarthritis" at Osteoarthritis Research Society International's (OARSI) 2013 World Congress on Osteoarthritis in Philadelphia. Flexion co-founder and chief medical officer, Neil Bodick, M.D., Ph.D., will discuss the findings during the poster session from 3:30 p.m....

2012-12-17 08:25:07

WOBURN, Mass., Dec. 17, 2012 /PRNewswire/ -- Flexion Therapeutics, Inc. today reported that FX006, its novel intra-articular, sustained release steroid, maintained therapeutic concentrations in the knee joint significantly longer than the most commonly prescribed immediate release (IR) steroid, triamcinolone acetonide (TCA) in a Phase 2 pharmacokinetic study. At six weeks, FX006, a sustained release formulation of TCA, remained in the joint at clinically active concentrations while the IR...

2012-09-24 02:27:19

MAPLE GROVE, Minn., Sept. 24, 2012 /PRNewswire/ -- Upsher-Smith Laboratories, Inc. is proud to support the National Eczema Association (NEA) during Eczema Awareness Month in October to help generate greater awareness about eczema, its treatments, and resources available to help those who suffer from the disease. Since topical corticosteroids are one of the most useful medications for treating eczema(1), Upsher-Smith is taking action to help patients by offering the...

2011-07-11 08:00:00

MAPLE GROVE, Minn., July 11, 2011 /PRNewswire/ -- Today Upsher-Smith Laboratories, Inc. announced the launch of Trianex(TM) 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment. Trianex(TM) combines triamcinolone, the No. 1 prescribed type of topical corticosteroid,(1) with a pleasing cream-like base to relieve inflammation and itching in skin conditions that respond to treatment with corticosteroids,...

2009-09-15 05:57:48

Injecting the eye with the corticosteroid triamcinolone appears effective in improving the vision of some patients with retinal vein occlusion, an important cause of vision loss that results from blockages in the blood vessels in the retina, according to two reports in the September issue of Archives of Ophthalmology, one of the JAMA/Archives journals. A 1-milligram dose of triamcinolone may be a treatment option for certain patients with blockages in the main portion of the retinal vein,...

2008-10-06 21:00:11

Thai researchers suggest patients on allergy medicine are better served when they adjust their dose to symptoms. The researchers found the effectiveness of intranasal corticosteroids -- a drug that reduces swelling and secretions in the nose -- could be achieved with three-quarters of the usually recommended daily dosage when patients were instructed how to vary the daily dosage in response to severity of symptoms. This new approach to dosing could help prevent the problem of increased...